drugset / Trial / NCT05046132
Study of Setmelanotide Effects on QTc (Corrected QT) Interval in Healthy Participants
RandomizedParallel-groupTriple-blindTreatment
Summary
This was a double-blind, randomized, placebo- and positive-controlled, parallel group, 3-arm study that assessed the potential for therapeutic and supratherapeutic concentrations of setmelanotide to affect the QTc corrected by the Fredericia method (QTcF) interval.
Timeline
- Start
- 2021-08-05
- Primary completion
- 2022-04-07
- Completion
- 2022-04-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Moxifloxacin | Small molecule | 400 mg | Oral |
| Subject | Setmelanotide | Protein / enzyme biologic | 7 mg | Subcutaneous |
Indications
No indication recorded.